Search results
Pfizer Stock Gets Boost From Better-Than-Expected Earnings
Investopedia· 4 days agoNet income was 44% lower at $3.12 billion, or 55 cents per share from last year's mark of $5.54...
FY2025 EPS Estimates for Pfizer Inc. Increased by Leerink Partnrs (NYSE:PFE)
ETF DAILY NEWS· 15 hours agoPfizer Inc. (NYSE:PFE – Free Report) – Equities research analysts at Leerink Partnrs boosted their FY2025 EPS estimates for shares of Pfizer in a research ...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 4 days agoThe RS Rating measures a stock's 12-month running performance against all other stocks. That RS...
Pfizer’s 44% Decline In Profits Still Tops Estimates—Stock Bounces From Decade Low
Forbes· 5 days agoThe company affirmed its full-year 2024 guidance of $58.5 billion to $61.5 billion in sales and...
3 No-Brainer Stocks to Buy in May
Motley Fool via Yahoo Finance· 7 hours agoConsider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $544,015!* Stock Advisor...
Pfizer (PFE) Q1 Earnings & Sales Top, EPS Guidance Raised
Zacks via Yahoo Finance· 4 days agoSI&A spending is expected in the range of $13...to $14.8 billion. The adjusted tax rate is expected...
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
CNBC· 4 days agoThe company now expects to book adjusted earnings of $2.15 to $2.35 per share for the fiscal year,...
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To...
Benzinga via AOL· 4 days agoOn Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year...
Pfizer lifts profit view on cost cuts, demand for COVID products
Reuters· 4 days agoSales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal...
Pfizer Earnings Top Views; Boosts Full-Year Guidance
Morningstar· 4 days agoBy Rob Curran Pfizer posted first-quarter earnings and sales that topped Wall Street targets and boosted its full-year projections as sales of blood thinners and cancer drugs ...
